Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Akcea Therapeutics.

    Client Virtual Booth

    AKCEA THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Akcea Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    22 Boston Wharf Road, 9th Floor, Boston MA 02210
    Telephone
    Telephone
    (617) 207-0202
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://akceatx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/akcea-therapeutics
    Twitter
    Twitter
    https://twitter.com/akceatx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (RX) ) at ESC Congress 2020

    Details:

    The Phase 2 dose-ranging clinical trial evaluated the safety and efficacy of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).


    Lead Product(s): Vupanorsen

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: AKCEA-ANGPTL3-LRx

    Highest Development Status: Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Ionis Pharmaceuticals

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 24, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

    Details:

    Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease.


    Lead Product(s): AKCEA-APOCIII-LRx

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: ISIS 678354

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 18, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

    Details:

    Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3.


    Lead Product(s): AKCEA-ANGPTL3-LRx

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Cell and Gene therapy

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 28, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

    Details:

    AKCEA-APOCIII-L Rx demonstrate favorable safety and tolerability were in hypertriglyceridemia patients in the study.


    Lead Product(s): AKCEA-APOCIII-LRx

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 22, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search